2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024, 86: 516-527. PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer expertsEfficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Kamat A, Bivalacqua T, Montgomery J, Lerner S, Busby J, Poch M, Crispen P, Steinberg G, Schuckman A, Downs T, Mashni J, Lane B, Guzzo T, Bratslavsky G, Karsh L, Woods M, Brown G, Canter D, Luchey A, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Sankin A, O’Donnell M, Sawutz D, Philipson R, Parker N, Yla-Herttuala S, Rehm D, Jakobsen J, Juul K, Dinney C. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. Journal Of Urology 2024, 212: 74-86. PMID: 38704840, DOI: 10.1097/ju.0000000000004020.Peer-Reviewed Original ResearchConceptsNonmuscle-invasive bladder cancerPhase 3 trialBladder cancerFollow-upAdenoviral vector-based gene therapyProgression to muscle-invasive diseaseOpen-label phase 3 trialVector-based gene therapyCystectomy-free survivalMuscle-invasive diseaseMedian follow-upCarcinoma in situBladder preservationNadofaragene firadenovecOverall survivalGene therapyCytological assessmentTa/T1PatientsUS sitesCohortReceiving treatmentMonthsCancerHGRFEFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
Boorjian S, Narayan V, Master V, Konety B, Shore N, Kamat A, Dinney C, Bivalacqua T, Kates M, Montgomery J, Lerner S, Crispen P, Steinberg G, Agarwal P, Schuckman A, Svatek R, Lane B, Karsh L, Bjurlin M, Brown G, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Kim E, Sankin A, O'Donnell M, Jakobsen J, Juul K. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL. Urologic Oncology Seminars And Original Investigations 2024, 42: s70. DOI: 10.1016/j.urolonc.2024.01.201.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerPhase 3 studyFollow-up resultsNadofaragene firadenovecCarcinoma in situPapillary diseaseTreatment optionsFollow-upProgression to muscle-invasive diseaseDiscontinuation due to adverse eventsOpen-label phase 3 studyVector-based gene therapyTreatment of adult patientsBenefit-to-risk ratioDuration of follow-upCystectomy-free survivalHigh-grade recurrenceMuscle-invasive diseaseDurability of responseDuration of CRInvasive bladder cancerMonths of treatmentNovel treatment optionsBCG-unresponsiveMultiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics
Anurag M, Strandgaard T, Kim S, Dou Y, Comperat E, Al-Ahmadie H, Inman B, Taber A, Nordentoft I, Jensen J, Dyrskjøt L, Lerner S. Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics. IScience 2024, 27: 109179. PMID: 38439961, PMCID: PMC10910238, DOI: 10.1016/j.isci.2024.109179.Peer-Reviewed Original ResearchCarcinoma in situCarcinoma in situ lesionsUrothelial carcinoma in situPapillary tumorsAggressive phenotypeAssociated with carcinoma in situNon-muscle-invasive bladder cancerCarcinoma in situ samplesPD-1-positive cellsImmune marker expressionBladder cancerImmunological landscapeMarker expressionTumorGene signatureMutational heterogeneityImmune characteristicsMutated genesExpression signaturesTargeting mTORHigher expressionTime pointsMutation analysisMultiomic profilingLesions
2023
Genomic Profiling of Urothelial Carcinoma <I>in Situ</I> of the Bladder
Anurag M, Strandgaard T, Kim S, Comperat E, Al-Ahmadie H, Inman B, Dyrskjot L, Lerner S. Genomic Profiling of Urothelial Carcinoma in Situ of the Bladder. EMJ Urology 2023, 11: 41-42. DOI: 10.33590/emjurol/10306009.Peer-Reviewed Original ResearchCarcinoma in situUrothelial carcinoma in situCarcinoma in situ lesionsPapillary tumorsWhole-exome sequencingBladder cancerInvasive cancerMolecular subtypesT cellsFFPE samplesAssociated with carcinoma in situPresence of cytotoxic T cellsProgrammed cell death protein 1Formalin-fixed paraffin-embedded (FFPE) tumorsAssociated with invasive cancerCarcinoma in situ samplesCell death protein 1Detecting carcinoma in situExome sequencingLevels of immune cellsRNA sequencingProbability of disease progressionHigh-grade lesionsRegulatory T cellsCytotoxic T cells